U.S. Markets open in 1 hr 16 mins

Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it right every time, but when you do, the returns can be truly splendid. One such superstar is Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), which saw its share price soar 393% in three years. And in the last month, the share price has gained 16%.

Check out our latest analysis for Dicerna Pharmaceuticals

Dicerna Pharmaceuticals isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 3 years Dicerna Pharmaceuticals saw its revenue grow at 107% per year. That's well above most pre-profit companies. And it's not just the revenue that is taking off. The share price is up 70% per year in that time. It's always tempting to take profits after a share price gain like that, but high-growth companies like Dicerna Pharmaceuticals can sometimes sustain strong growth for many years. So we'd recommend you take a closer look at this one, or even put it on your watchlist.

The chart below shows how revenue and earnings have changed with time, (if you click on the chart you can see the actual values).

NasdaqGS:DRNA Income Statement, June 18th 2019

Balance sheet strength is crucual. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

It's nice to see that Dicerna Pharmaceuticals shareholders have received a total shareholder return of 26% over the last year. Notably the five-year annualised TSR loss of 2.5% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. You could get a better understanding of Dicerna Pharmaceuticals's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.